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ABSTRACT 
 
Introduction: Oral Melanoma is a rare entity accounting for 0.8 to 8% of all melanomas 
and 0.5% of all oral neoplasms. The melanocytic lesions that appear on the oral cavity 
are based on genetic mechanisms with no association to ultraviolet (UV) light exposure, 
but the etiologic factors for the former are not established yet. Oral melanoma usually 
develops in people over 50 years old and has a male predisposition. The palate and 
maxillary gingiva are the most affected sites. In the majority of cases oral melanoma is 
an asymptomatic disease, without pain in early stages, which contributes to the delay in 
the diagnosis. 
Objective: This work aims to review the existing literature related with oral melanoma, 
detailing its molecular and histopathological alterations. 
Materials and Methods: A comprehensive literature review was performed using the 
PubMed, Medline, EBSCO and SCOPUS electronic databases, in order to identify 
publications about Oral Mucosal Melanoma, in the English language, between 2006 and 
2016, and with full text available. 
Discussion: The American Joint Committee on Cancer (AJCC) considered necessary the 
creation of a separate classification system from the one used for all other neoplasms of 
the head and neck region, which reflected the high recurrence rate and low overall 
survival of oral mucosal melanoma. The 5-year survival rate reported for oral melanoma 
ranges from 12% to 55%.  
The most common mutation harbored in oral melanoma is found in the tyrosine-
protein kinase (KIT). Mutations on v-raf murine sarcoma viral oncogene homolog B1 
(BRAF) oncogene are uncommon in oral melanoma and are more frequent in cutaneous 
melanoma. Alterations in p53 gene allow oral melanoma to metastasize and have a more 
aggressive pattern.  
Oral melanoma is an aggressive disease with high tendency to local recurrence 
and metastization. The best chance of survival is associated with the complete surgical 
removal of the tumor with negative margins. Radiotherapy, chemotherapy and 
immunotherapy can be used as adjuvants after ressective surgery. 
Conclusion: Oral mucosal melanoma and cutaneous melanoma differ greatly with 
respect to biological behavior and genetic alterations. Consequently, further prospective 
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studies and randomized clinical trials are required in order to better understand oral 
melanoma and to validate the optimal treatment protocols. Dental professionals play a 
critical role in the detection of mucosal melanoma, as throughout the clinical examination 
conducted in routine medical appointments, they should be alert to any alterations in the 
oral cavity. 
 
Key Words: Melanoma, Oral Melanoma, Mucosal Melanoma, Oral Malignant 
Melanoma, Histopathological alterations, Molecular alterations. 
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RESUMO 
 
Introdução: O melanoma oral é uma entidade rara que representa 0,8 a 8% de todos os 
melanomas e 0,5% de todas as neoplasias orais. As lesões melanocíticas que aparecem na 
cavidade oral têm origem em mecanismos genéticos que não estão associados com a 
exposição à luz ultravioleta, mas os seus fatores etiológicos ainda não estão 
completamente estabelecidos. O melanoma oral desenvolve-se em pessoas com mais de 
50 anos de idade e mais frequentemente em homens. Os locais mais afetados são o palato 
e a gengiva maxilar. Na maioria dos casos o melanoma oral é uma doença assintomática, 
sem dor nas fases iniciais, o que contribui para o atraso no seu diagnóstico. 
Objetivo: Este trabalho visa a realização de uma revisão da literatura existente acerca do 
melanoma oral, detalhando as suas alterações moleculares e histopatológicas. 
Materiais e Métodos: Recorreu-se às bases de dados eletrónicas PubMed, Medline, 
EBSCO e SCOPUS, de forma a identificar publicações sobre o melanoma da mucosa 
oral, em Inglês, entre 2006 e 2016, e com texto integral disponível. 
Discussão: O American Joint Committee on Cancer (AJCC) considerou necessária a 
criação de um sistema de classificação separado do usado nas restantes neoplasias da 
cabeça e pescoço, que refletisse a alta taxa de recorrência e a baixa sobrevida global do 
melanoma da mucosa oral. A taxa de sobrevivência a 5 anos, para o melanoma oral, varia 
entre 12% a 55%.  
A mutação mais comummente encontrada no melanoma oral é na proteína 
tirosina-quinase KIT (KIT). Mutações no Homólogo B1 do oncogene viral de sarcoma 
murino v- raf (BRAF) são muito raras no melanoma oral e mais frequentes em pacientes 
com melanoma cutâneo. Alterações no gene p53 conferem ao melanoma oral a 
capacidade de metastizar e a aquisição de um padrão mais agressivo.  
O melanoma oral é uma doença agressiva, com alta tendência para a recorrência 
local e metastização. A melhor hipótese de sobrevivência está associada à remoção 
cirúrgica completa do tumor com margens negativas. A radioterapia, quimioterapia e 
imunoterapia podem ser utilizadas como adjuvantes, após a cirurgia ressectiva. 
Conclusão: O melanoma da mucosa oral e o melanoma cutâneo são muito diferentes 
relativamente ao comportamento biológico e às alterações genéticas. Assim, são 
necessários mais estudos prospetivos e ensaios clínicos randomizados de forma a 
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compreender melhor esta condição patológica e a validar protocolos de tratamento 
adequados. O Médico Dentista desempenha um papel fundamental na deteção do 
melanoma oral, pois durante o exame clínico que realiza em todas as consultas deve estar 
alerta a quaisquer alterações na cavidade oral. 
 
Palavras-Chave: Melanoma, Melanoma Oral, Melanoma da Mucosa, Melanoma 
Maligno Oral, Alterações Histopatológicas, Alterações Moleculares. 
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INTRODUCTION 
 
Melanocytes are the pigment producing cells of the body which derive from the 
neural crest and migrate to the skin and mucosa, during embryogenesis. (1-3) Apart from 
the skin, melanocytes can also be found in mucosal surfaces of the body that derive from 
the ectoderm, such as sinuses, nasal passages, oral cavity, vagina, anus and conjunctiva. 
(4-6) Skin melanocytes have a protective function against the harmful effects of sun 
exposure; however, the function of these cells in the mucosa is still largely unknown. (7) 
When melanin production or melanocyte proliferation occurs, a wide range of 
occurrences can develop, ranging from physiologic pigmentations to malignant 
neoplasms. (7) If melanocytes suffer malignant transformation, melanoma develops. (7, 
8) 
Oral Melanoma is a rare entity accounting for 0.8 to 8% of all melanomas and 
0.5% of all oral neoplasms. (2, 4, 9)  Head and Neck Mucosal Melanomas (HNMM) 
account for less than 10% of the melanomas that develop on the head and neck region (4, 
7), half of which appear on the oral cavity. (7, 10) The World Health Organization defined 
mucosal melanoma as a malignant neoplasm of melanocytes or of melanocytes’ 
precursors. (10) According to the Melanoma Research Foundation, mucosal melanoma is 
a rare form of melanoma that occurs in the mucous membranes, such as the nasal 
passages, throat, vagina, anus or mouth, making up only about 1% of melanoma cases. 
(6) 
Oral melanoma was first described by Weber in 1859 and recognized as a clinical 
entity by Lucke in 1869. (11) The incidence of HNMM is approximately 4 per 10 million 
individuals, per year, in the USA, and for oral melanoma specifically, is around 1.2 cases, 
per 10 million individuals, per year. (7, 12) Mucosal melanomas are more frequent in 
some areas of Africa, Japan or Uganda than in Western countries. (4, 13, 14)  
Despite the majority of malignant melanocytic lesions appear on the skin, about 
90%, they can develop anywhere in the body where melanocytes are found. (9) The 
melanocytic lesions that appear on the oral cavity are based on genetic mechanisms with 
no association to UV light exposure, as it happens for the lesions on the skin. However, 
the etiologic factors for the formers are not established yet. In fact, no obvious risk factors 
or even family history was associated with oral melanoma development. (4, 15, 16) 
Oral Melanoma: Histopathological and Molecular Alterations 
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Regardless, some authors believe that tobacco use and chronic irritation can influence the 
development of mucosal melanoma. (4, 17) 
Oral melanoma appears initially as a highly pigmented macule, colored black or 
brown, with ill-defined and irregular borders (10, 18), which can later originate a nodule 
or an ulcer. (19) In the upper aerodigestive tract, oral and sinus cavities are the most 
affected areas. (4) Usually, oral melanoma develops in people over 50 years old, with an 
average age of 61 years (4, 9, 20), more frequently on males. (9, 17, 20) The most 
common sites in the oral cavity are the palate and maxillary gingiva (80% of the cases), 
but it can also be found on the lips, jugal mucosa and floor of the mouth. (4, 17, 21) Oral 
melanoma lesions can be pigmented or amelanotic, which represents a greater challenge 
in diagnosis. (6, 22) 
In the majority of cases oral melanoma is an asymptomatic disease, without pain 
in early stages, which contributes to the delay in the diagnosis. (13) For that reason, 
mucosal melanoma usually presents itself as a large lesion in an advanced stage, at 
diagnosis. (23) 
Some authors believe that oral melanoma lesions should not be biopsied, but 
completely excised, because incisional biopsy can cause the risk of dissemination of 
malignant melanocytes and lead to metastization. (4, 19, 24) However, despite the 
absence on the identification of any precursor lesion, one third of the patients had 
preexistent mucosal melanosis. (1, 4, 13) Therefore, other authors believe that it is 
mandatory to perform an incisional biopsy of these pigmented lesions, as well as other 
suspicious lesions, to rule out the diagnosis of oral melanoma. (1, 13, 17) In fact, the 
majority of mucosal melanomas arise de novo from an otherwise normal mucosa, but 
about 30% are preceded by oral pigmentation for several months or years. (4, 14, 17) 
To confirm the diagnosis, a panel of immunohistochemical markers is usually 
performed using the S-100 protein, Melan-A, HMB-45, tyrosinase (T311), 
microphthalmia transcription factor (Mitf), Vimentin and also by the demonstration of 
intracellular expression of melanin. (1, 13, 17) 
Mucosal melanoma is a very aggressive disease, rated among the most malignant 
epithelial tumors of the human body, with tendency to local recurrence and distant 
metastasis. (4, 14, 16) Ressective surgery is the primary modality of treatment advocated 
by the majority of the authors (4) but it can be associated with radiotherapy, chemotherapy 
and immunotherapy, even though the effectiveness of these therapies, either as primary 
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treatment or in combination with surgery, is largely unknown. (13, 16, 17) The leading 
cause of death is systemic recurrence of the disease (4) and therefore, the majority of 
patients with HNMM will not survive beyond 5 years. (2)  
Due to its rarity and the difficulty of developing prospective studies, oral 
melanoma is poorly described and little studied. As a result, there is a lack of data 
regarding its epidemiology, etiology and pathogenesis, and the establishment of 
standardized therapeutic guidelines is a great challenge. Hence, there is no consensus on 
the optimal systemic therapy. (2, 17, 25) The best chance of survival is associated with 
the complete surgical removal of the tumor with negative margins. However, wide free 
margins are difficult to obtain in the head and neck region without high morbidity and 
profound changes in the quality of life of the patients. (1, 3, 4) Early diagnosis and a 
multimodal aggressive treatment are the only means available to the medical community 
to offer the best results to patients with mucosal melanoma. (3)  Patient prognosis can 
also be enhanced if the cancer is detected early and managed properly. (26) 
In accordance, this work aims to review the existing literature on oral melanoma, 
detailing the molecular and histopathological alterations. Since oral melanoma is such a 
rare and aggressive disease for which etiological factors and optimal treatment strategy 
have not yet been defined, it is crucial to understand the molecular level alterations, 
verified in this condition. The study of the most common mutations affecting KIT, p53, 
p16 and many other molecular pathways, enables the understanding of the mechanisms 
behind oral melanoma development and their trigger factors, in ways that promote the 
adequacy of existing therapeutic approaches and the establishment of new therapies.  
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MATERIALS AND METHODS 
 
A comprehensive literature review was performed using the PubMed, Medline, 
EBSCO and SCOPUS electronic databases, in order to identify publications about Oral 
Mucosal Melanoma, in the English language, between 2006 and 2016, and with full text 
available. The following search terms were used: “oral melanoma”, “oral melanoma AND 
histopathological alterations”, “oral melanoma AND molecular alterations”, “oral 
malignant Melanoma AND histopathological alterations”, “mucosal melanoma AND 
molecular alterations”, “mucosal melanoma AND histopathological alterations”. The 
articles used for this paper were selected based on the review of the abstract and the 
relevance to the topic.  
In addition to the articles resulting from the research in the mentioned databases, 
other articles, found to be relevant to the topic were also included, as well as information 
collected from reference books in the field of Oral Pathology, as indicated in the 
References section. 
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DISCUSSION 
 
 
ETIOLOGY 
 
Oral melanoma is a rare clinical entity with an undefined etiology and broadly 
unknown risk factors. In this way, it is not possible to prevent the establishment or 
development of this neoplasm, or even to identify patients at higher risk for development 
of oral melanoma. Regardless, some authors have suggested the possible role of tobacco 
use, formaldehyde exposure, chronic irritation (e.g. ill-fitting dentures) and exposure to 
inhaled and ingested environmental carcinogens at high body temperatures, in the 
transformation of melanocytes. (14, 17, 27) Regardless all the above mentioned, a study 
by Furney, et al., demonstrated that the genetic mutations found in oral melanoma cells 
were not the same as the ones caused by tobacco use in other neoplasms. This lead to the 
idea that tobacco use may not be involved in oral melanoma development. (28) 
In the majority of cases oral melanoma is asymptomatic, but symptoms such as 
swelling, bleeding, ulceration, pain, ill-fitting dentures, tooth mobility, pigmented lesions, 
delayed healing of extraction sites or bone erosion may be present in a later stage of the 
disease. (29-31) Therefore, the diagnosis happens in a delayed fashion and mostly by 
accident, and not because the patient suspected of any changes in the oral cavity. (14, 29) 
All of these factors contribute to a very poor prognosis. 
 
 
CLINICAL DIAGNOSIS 
 
Clinically, oral melanoma diagnosis cannot be made using the ABCDE rule, as 
for cutaneous melanoma. Given the fact that signals such as asymmetry, irregular borders, 
irregular color, dimensions larger than 6 mm in diameter and elevation of the lesion 
appear late in the course of the disease and in situations in which there is already 
significant vertical invasion of tumor cells into the underlying tissue, clinicians should 
not apply the former rule. (17) Therefore, mucosal melanoma can be clinically staged as: 
Stage I - lesion limited to the primary site (Tany N0M0); Stage II - lesion associated with 
lymph node metastasis (Tany N1M0) and Stage III - lesion associated with distant 
metastasis (Tany N1M1). (16, 17) 
Oral Melanoma: Histopathological and Molecular Alterations 
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HISTOLOGICAL DIAGNOSIS 
 
Given the fact that the majority of HNMM (71 to 91%) are localized and identified 
in Stage I, and the classification system mentioned above gives great importance to 
metastization, Prasad et al., developed a microstaging system with 3 levels for stage I. 
Level I - in situ melanoma with no evidence of invasion or microinvasion (microinvasion 
is defined as the presence of individual or agglomerated invasive melanocytes with fewer 
than 10 atypical melanocytes near the subepithelial junction); Level II - melanoma cells 
limited to the lamina propria; and Level III - invasion of the deep connective tissue, 
including skeletal muscle, bone, or cartilage. Level I is defined above the epithelial 
basement membrane, Level II below the epithelial basement membrane but above the 
perimysium, or periosteum, or perichondrium and Level III represents invasion through 
the perimysium, periosteum, or perichondrium. According to these authors, histological 
level constitutes one of the most important histopathological predictors of poor survival. 
Hence, the breakage of each of the barriers represents a worse prognosis. (16) 
Furthermore, oral melanomas can be classified as: in situ melanoma, when the 
lesion is confined to the epithelium and the epithelial-connective tissue interface; invasive 
melanoma, if it is extended into the connective tissue; and lesions with a combined pattern 
of invasive melanoma with in situ component. (7, 10, 17) The majority of mucosal 
melanoma lesions are identified during vertical growth phase and with an invasive or 
combined pattern. (7, 10) Despite, histological staging of these tumors is not yet 
completely defined and due to anatomical differences between the mucosa and the skin, 
the histological microstaging methods of Clark and Breslow's thickness, used on 
cutaneous melanoma, may not be suitable for the mucosal melanoma staging. (16, 17) 
Oral melanoma cells exhibit a broad range of cellular morphological features on 
which spindle shaped, plasmacytoid, epithelioid and “clear” cells can be identified. (17) 
In the majority of cases the mucosal melanoma cell population is polymorphic. (32) 
Despite, spindle and epithelioid cells are the most commonly found, often in combination. 
(32, 33) The microscopic patterns in which mucosal melanoma cells can be arranged 
include sheet-like, organoid, alveolar, solid, neurotropic or desmoplastic. (8, 10, 34)  
According to the literature, patients with non-epithelioid cell oral melanoma seem 
to have a better prognosis, with expected increased survival. In contrast, patients with 
epithelioid cell mucosal melanoma exhibit a higher risk for the development of distant 
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metastasis and a worse prognosis, suggesting the association with a more aggressive 
variant of the tumor. (6) 
Neoplastic melanocytes exhibit hyperchromatic, angular and large nuclei with 
prominent nucleolus and infrequent mitotic figures. (7, 10, 17) Furthermore, these cells 
have lost contact inhibition that characterizes melanocytes, thus being able to form cell 
clusters. (7, 17) 
Given the wide spectrum of forms which melanoma cells can adopt, the lesion 
may mimic other malignancies such as sarcoma, plasmacytoma, carcinoma, 
neuroendocrine lesions or papilloma (e.g. spindle cell oral melanoma can mimic sarcoma; 
epithelioid mucosal melanoma may suggest salivary carcinoma; plasmacytoid oral 
melanoma may resemble olfactory neuroblastoma or plasmacytoma) (29) 
 
 
DIFFERENTIAL DIAGNOSIS 
 
Differential diagnosis of all lesions which may mimic this neoplasm is a crucial 
step in the diagnosis of oral melanoma. According to all the literature available on this 
subject, differential diagnosis may include benign pigmented lesions such as melanotic 
macule, melanosis associated with tobacco use, drug induced pigmentation, 
melanoacanthoma, melanotic nevus, racial pigmentation, vascular lesions, pigmentation 
associated with systemic disease (e.g. Addison disease or Peutz-Jeghers syndrom) 
amalgam tattoo and post-inflammatory pigmentation; malignant pigmented lesions of 
which Kaposi sarcoma is an example. Amelanotic melanomas must be differentiated from 
a variety of non-pigmented neoplasms, such as sarcomas, poorly differentiated 
carcinoma, lymphoma and small cell carcinoma. (3, 8, 32) 
 
 
IMMUNOHISTOCHEMICAL DIAGNOSIS 
 
The immunohistochemical diagnosis in oral melanoma is performed using 
melanocyte differentiation markers such as Melan-A, HMB-45, tyrosinase and Mitf. 
Mucosal melanoma cells also express Vimentin and S-100 protein. (1, 9, 13) Another way 
to confirm the diagnosis is through the demonstration of intracellular expression of 
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melanin. (1, 9, 13) Oral melanomas do not express cytokeratins and epithelial membrane 
antigens. (10, 13) The clinical diagnosis of amelanotic melanomas presents a great 
challenge, hence immunohistochemical diagnosis is essential. 
Mitf is a melanocytic nuclear protein which plays a crucial role in melanocytes 
embryonic development, postnatal viability and pigmentation. (35) T311 is a critical 
enzyme during melanin biosynthesis, being a sensitive and specific marker for melanoma. 
(36) Comparing the immunological markers used nowadays in oral melanoma diagnosis, 
Mitf is more specific than S-100 protein and is as specific as HMB-45. (35) S-100 protein 
and T311 seem to have a higher sensitivity when compared with HMB-45, but the latter 
seems to be more specific. (3, 32) Despite that, there is not a unique melanocyte marker 
with 100% sensitivity. (32) 
 
 
HISTOPATHOLOGICAL AND MOLECULAR ALTERATIONS 
 
As occurs in most human cancers, the malignant transformation of melanocytes is 
dependent upon the sequential accumulation of molecular and genetic alterations that 
seem to be independent of UV light exposure. (8, 27) Therefore, the biologic behavior of 
oral melanoma must be different from its cutaneous counterpart. However, the genetic 
and environmental risk factors implicated in oral melanomagenesis have not been 
described. (28) Considering that the results of cutaneous melanoma studies do not 
necessarily apply to mucosal melanomas, there is a need to further investigate this entity 
and develop a proper diagnosis and therapeutic approach. (37-39) 
The most common mutation harbored in oral melanoma is found in the tyrosine-
protein kinase KIT (KIT) (15-39% of the cases). (3, 28, 38) This protein has a critical 
function in the normal development and activity of melanocytes in the embryonic and 
postnatal stages. (8) Therefore, genetic aberrations affecting KIT oncogene, such as 
amplifications or activating mutations, play an important role in tumor growth and 
therapeutic approaches. In fact, there are case reports which demonstrate the clinical 
activity of KIT inhibitors, such as Imatinib, in melanoma treatment. (3, 40) 
p53 mutations are one of the most prevalent events in human cancers, including 
mucosal melanoma, on which is detected in around 2/3 of the cases. (7, 17) p53 is a tumor 
suppressor gene and when DNA is excessively damaged, p53 protein promotes G1 arrest, 
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increases the function of DNA repair genes and induces apoptosis. (41) If p53 protein is 
mutated, it fails to regulate cell cycle and, therefore, to induce apoptosis, imparting the 
cell resistance to chemotherapy and radiotherapy. (31) This abnormality is associated 
with the ability of the neoplasm to metastasize, and associated with a more aggressive 
pattern of the disease. (7) In cutaneous melanoma, mutation of p53 is uncommon. (41) 
According to Tanaka, et al., in oral melanoma, genetic aberrations affecting p53 are 
correlated with high stage development of the neoplasm. (39) In summary, alterations in 
p53 can function as a predictor of the malignant potential of oral melanoma and be used 
in diagnosis, prognosis and therapeutic approach. (39) 
Cyclin-dependent kinase inhibitor 2A (p16) inhibits melanocytic proliferation 
leading to cell arrest, through the activation of p16cdkn2a pathway, which prevents the 
cell cycle to progress from G1 to S phase. (41) Therefore, alterations in this pathway leads 
to uncontrolled cell growth. The p16cdkn2a pathway is involved in the development of 
melanoma in sites with less sun exposure and the loss of p16 expression was identified in 
about 50% of oral melanomas. (8, 42)  
Mutations in p53 and inactivation of p16 are early events in tumorigenesis of 
mucosal melanoma and are associated with worse prognosis. (41, 43) These abnormalities 
suggest that the loss of programmed cell death and G1/S arrest play a role in the 
development of oral melanoma. (41, 42) 
Oral melanocytic nevi are one of the differential diagnosis for oral melanoma. 
These lesions are more prevalent in the palate, which is the most common site for mucosal 
melanoma development in the oral cavity. (7, 44) This has led some authors to support 
that oral melanocytic nevi represents a precursor lesion of oral melanoma. (30, 44) 
However, in a study by Andrade et al., p16 expression in oral melanocytic nevi was not 
altered, leading to the conclusion that the former benign lesion may not be a precursor of 
oral melanoma. (42) Regardless, oral melanocytic nevi prophylactic excision is 
recommended since their nature is unknown. (7) 
B-cell lymphoma 2 (Bcl-2) encodes an anti-apoptotic protein that may also be 
mutated in oral melanoma. Its function is to prolong cell survival. (41) Expression of Bcl-
2 is also an early event in tumorigenesis but, contrary to p53 and p16, it predicts better 
prognosis and longer survival of the patients. (41) 
Mutations on v-raf murine sarcoma viral oncogene homolog B1 (BRAF) oncogene 
are uncommon in oral melanoma and can only be found in 10% of the cases. (3, 40) 
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Furthermore, the abnormalities found on BRAF are highly associated to neoplasms arising 
in sites with intermittent sun exposure. (45, 46) 
Lower incidence of BRAF oncogene mutations associated with a higher incidence 
of KIT oncogene mutations suggest a divergent genetic etiology and renders to oral 
melanoma uniqueness, when compared to the cutaneous counterpart. (13, 25) 
Cyclin D1 (CCDN1) is a positive regulator of the G1/S checkpoint of the cell 
cycle. (42) In a study by Andrade et al., an increased expression of this molecule in oral 
melanomas was verified, as it happens in cutaneous and uveal melanomas, suggesting 
that cyclin D1 has a role in the pathogenesis of oral melanoma. (42) Cyclin-dependent 
kinase 4 (CDK4), a member of the cyclin dependent kinase (cdk) family, encodes a 
protein that binds to CCND1, allowing cell cycle progression. (46) In a study of Curtin, 
et al., amplifications in CDK4 protein were more frequent in acral and mucosal 
melanomas. (46) p16, which functions has a negative regulator for CDK4-CCDN1 
complex, also showed losses in its locus, more commonly in mucosal and acral 
melanomas, losing the ability to control G1/S checkpoint. (46) If CDK4 is amplified, it 
excessively binds to CCDN1 leading to an uncontrolled progression of the cell cycle, 
increasing oral melanoma growth. (46) 
Retinoblastoma (Rb) gene and the pRb2/p130 protein are growth suppressor 
agents, which are dysfunctional in several neoplasms. (39) According to Tanaka, et al., 
patients whose tumors were positive for pRb2/p130, had a higher 5-year cumulative 
survival rate when compared with pRb2/p130 negative tumors. (39) Thus, pRb2/p130 
protein expression was associated with low stage of development of oral melanoma and 
a better clinical outcome. (39) 
p21, a cyclin-dependent kinase inhibitor, functions as a tumor suppressor and its 
downregulation is associated to tumor invasiveness and metastasis formation. In 
melanoma, its expression is lower in metastatic, rather than in primary lesions, indicating 
a more aggressive phenotype. (42) 
p27, a cyclin-dependent kinase inhibitor, is a suppressor of the G1/S cell cycle 
transition. (42) p27 protein is highly expressed in benign lesions and it is lost as melanoma 
develops. (42) It has been demonstrated that the loss of heterozygosity (LOH) in the gene 
locus 12p13 leads to the loss of p27 protein expression, allowing melanoma progression 
and the formation of metastasis. (17, 42, 47) 
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There are many other molecular pathways altered in melanoma that may assist on 
the explanation on how this disease develops. Mitf, which is regulated by KIT, regulates 
important genes for melanoma proliferation and it is amplified in approximately 15-20% 
of melanomas. (8) Phosphatase and Tensin Homolog (PTEN), a part of the 
phosphatidylinositol 3' kinase (PI3K) pathway, is a tumor suppressor gene responsible 
for regulating cell division, migration, spreading and apoptosis, which is also depleted in 
melanoma, contributing to tumor growth. (8, 46) The dysregulation of the Mitogen-
activated protein kinase (MAPK) pathway, also known as Ras/Raf/MEK/ERK pathway, 
plays a crucial role in the development of various neoplasms, including melanoma, since 
it regulates cell survival, invasion and growth. (8, 33) The alterations in this pathway are 
associated with the mutations of several genes, such as Ras, B-Raf, PI3K, PTEN and Akt. 
(33) Since this pathway is constitutively activated in the majority of human melanomas, 
cells seem to be able to resist to programmed cell death, allowing tumor cells to growth 
and proliferate. (33, 48)  
 Melanocyte-specific gene 1 (MSG-1) may be useful for the understanding of oral 
melanoma pathogenesis given the fact that it is thought to be involved in embryogenesis, 
melanogenesis and malignant transformation of melanocytes. (17, 37) However, in a 
retrospective study by Sedghizadeh et al., MSG-1 was expressed in only one mucosal 
melanoma case. Thus, this gene may be more associated with tumor development induced 
by UV light. (37) 
 
 
STAGING 
 
A specific staging system for oral melanoma has been established in 2010. (49) 
Prior to this date, patients were staged according to the tumor node metastasis (TNM) 
classification system of the AJCC, as for the cutaneous melanoma. This was a very simple 
staging system and did not reflect the true prognostic factors of oral melanoma. (2, 3)  
According to the AJCC, a neoplasm can be classified has: Stage I - generally 
denotes cancers that are smaller or less deeply invasive with negative nodes; Stage II and 
III - defines cases with increasing tumor or nodal extent; and Stage IV - identifies those 
who present with distant metastases (M1), at diagnosis. (49)  
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Due to the aggressive nature of mucosal melanoma represented by the high 
recurrence rate and low overall survival, the AJCC considered that it was necessary to 
create a separate classification system from the one used for all other neoplasms of the 
head and neck region, which reflected these characteristics. Thus, the staging system for 
HNMM starts with Stage III, for primary cancers limited to the mucosa. (Tables 1 to 4). 
(13, 49) Lesions in an advanced stage are classified as T4a and T4b and stages I and II 
are not recognized for mucosal melanoma. Moreover, in situ mucosal melanoma was 
considered extremely rare by the authors and also excluded from the staging. (49) 
 
Table I: AJCC Staging system for HNMM - Primary Tumor. Adapted from EDGE, et al., 2010. (49) 
Primary Tumor 
T3 Mucosal disease 
T4a 
Moderately advanced disease: Tumor 
involving deep soft tissue, cartilage, bone, 
or overlying skin 
T4b 
Very advanced disease: Tumor involving 
brain, dura, skull base, lower cranial 
nerves (IX, X, XI, XII), masticator space, 
carotid artery, prevertebral space, or 
mediastinal structures 
 
Table II: AJCC Staging system for HNMM - Regional Lymph Nodes. Adapted from EDGE, et al., 2010. 
(49) 
Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis present 
 
Table III: AJCC Staging system for HNMM - Distant Metastasis. Adapted from EDGE, et al., 2010. (49) 
Distant Metastasis 
M0 No distant metastasis 
M1 Distant metastasis present 
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Table IV: Anatomic stage and prognostic groups for HNMM. Adapted from EDGE, et al., 2010. (49) 
ANATOMIC STAGE/PROGNOSTIC GROUPS 
Stage III T3 N0 M0 
Stage IVA 
T4a N0 M0 
T3–T4a N1 M0 
Stage IVB T4b Any N M0 
Stage IVC Any T Any N M1 
 
 
TREATMENT 
 
As it was mentioned before, the overall survival rate for oral melanoma is low, in 
fact the 5-year survival rate ranges from 12% to 55%. (9, 50, 51) Furthermore, this is a 
very aggressive disease with tendency to local recurrence, which ranges from 64 to 92% 
(1, 52), and distant metastasis. (4, 14, 16) In contrast with cutaneous melanoma, the 
optimal treatment protocol for oral melanoma remains undefined. (53) 
Oral mucosa is composed of an epithelial layer, lamina propria and the 
submucosa. The lamina propria is thin and the absence of a reticular layer, as opposing 
to the skin, enables oral melanoma cells to spread more rapidly than those in the cutaneous 
melanoma. Therefore, mucosal melanomas infiltrate and metastasize quicker and have a 
worse prognosis than their cutaneous counterpart. (4, 21) The leading cause of death is 
systemic recurrence of the disease and the majority of patients with HNMM will not 
survive beyond 5 years. (2, 4) In fact, mucosal melanoma metastatic cells can infiltrate 
any organ in the body but they have a clear predisposition for the lungs, liver, brain, lymph 
nodes and intestine. For that reason, the majority of patients die of disseminated disease. 
(4, 9, 16) This demonstrates the need for the development of systemic therapy for oral 
melanoma to prevent metastization, and that local control does not equal to patients long-
term survival. However, until the present, no systemic therapy has been recognized as 
effective in the treatment of oral melanoma. (3, 50, 54) 
The mainstay of treatment is wide ressective surgery with clear margins (ideally, 
at least 1.5 cm of normal tissue), since it offers the best chance of survival and local 
control for Stages III and IVA lesions. (9, 13, 55) Surgery can be associated with 
radiotherapy, chemotherapy and immunotherapy, even though the effectiveness of these 
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therapies, either as primary treatment or in combination with surgery, is largely unknown. 
(9, 13, 17)  
For Stages IVB and IVC surgery is not recommended, so radiotherapy is used as 
primary treatment, and chemotherapy and immunotherapy as adjuvants. (13)  
The majority of the studies suggest that postoperative radiotherapy increase local 
control but without increasing survival rate, due to the high incidence of distant 
metastasis. (55-57) Its use is also critical in cases of positive margins after surgery, and 
also for inoperable cases. (53, 55, 56)  
Chemotherapy is mostly used as an adjuvant or palliative treatment, as well as 
immunotherapy (e.g. IFN α, Ipilimumab), but both with poor outcomes and no 
improvement on prognosis. (4, 53, 56) Mucosal melanomas express Cancer Testis 
Antigens (CTA) which can be used as a target for immunotherapeutic treatment, using 
monoclonal antibodies to CTAs. (27)  
Biochemotherapy has considerable activity against this neoplasm and has already 
demonstrated correlation with improved survival in patients with advanced and metastic 
disease. (50, 58)  
In cases of Kit mutations, Imatinib, a Kit inhibitor, can be used with therapeutic 
benefits. (38, 40) If the tumor is Bcl-2 positive, therapies to down-regulate this anti-
apoptotic oncogene can be considered for treatment purposes. (41) 
The use of sentinel lymph node is not completely defined in oral melanoma. (17, 
53, 58) However, the high tendency to regional relapses associated with oral melanoma 
highlights the need for treatment of positive cervical lymph nodes. Hence, if lymph node 
metastasis are clinically detected, elective neck dissection should be performed (Level I 
to III). The most recent studies demonstrate the necessity to perform elective neck 
dissection for oral melanomas since there is a higher risk of cervical lymph node 
metastasis, when compared with other HNMM. (13, 54, 56) 
The benefits of the use of adjuvant therapy in terms of survival for oral melanoma 
patients remains to be proven with randomized prospective clinical trials. (57, 58) Until 
then, clinicians will continue to extrapolate the results from cutaneous melanoma studies.  
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CONCLUSION 
 
Nowadays the medical community continues to adequate the knowledge obtained 
with cutaneous melanoma studies and its treatment strategies to oral melanoma cases. 
This constitutes the wrong approach given the fact that, as we could conclude from this 
work, these neoplasms differ greatly with respect to both the biological behavior, as well 
as the genetic alterations known to trigger disease establishment and development. As 
there are no prospective studies on this subject, treatment protocols are based in the 
clinical knowledge of the medical oncologist or surgeon, which is at the basis of the 
scientific evidence pyramid. Hence, further prospective studies and randomized clinical 
trials are required in order to better understand oral melanoma and to validate the optimal 
treatment protocols, which offers patients an improvement in outcome and a longer 
survival rate. Due to the fact that oral melanoma is extremely rare, these studies have to 
be multicentric. 
Dental professionals play a critical role in the detection of mucosal melanoma, as 
throughout the clinical examination conducted in routine medical appointments, they 
should be alert to any alterations in the oral cavity. Particular attention must be given to 
any changes in color of the mucosa of the palate and maxillary gingiva.  
Despite being a controversial subject, the majority of the reference treatment 
centers, as well as the AJCC, advocate the incisional biopsy for oral melanoma diagnosis. 
Therefore, the best approach for prevention is to conduct a biopsy whenever there are 
doubts on clinical diagnosis, as the consequences which come from a delayed diagnosis 
are ominous to the patients’ lives. 
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